Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

U.S. FDA approves new indication for Orion-Bayer prostate cancer drug
8 Jun 2025, 20:27ORNBV.HENASDAQ Helsinki

Filings

Recent filings

FilingDate
ORION CORPORATION SHARE REPURCHASE 21.0121 Jan 2003
ORION CORPORATION SHARE REPURCHASE 20.0120 Jan 2003
ORION CORPORATION SHARE REPURCHASE 17.0117 Jan 2003
ORION CORPORATION SHARE REPURCHASE 16.0116 Jan 2003
ORION CORPORATION SHARE REPURCHASE 15.0115 Jan 2003
ORION CORPORATION SHARE REPURCHASE 14.0114 Jan 2003
ORION CORPORATION SHARE REPURCHASE 13.0113 Jan 2003
ORION CORPORATION SHARE REPURCHASE 09.0110 Jan 2003
Search

Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).

  • Previous
  • 1
  • 2
  • Next
ORION CORPORATION SHARE REPURCHASE 10.0110 Jan 2003
ORION CORPORATION SHARE REPURCHASE 09.019 Jan 2003
ORION CORPORATION SHARE REPURCHASE 08.018 Jan 2003
ORION CORPORATION SHARE REPURCHASE 07.017 Jan 2003
  • Previous
  • 1
  • More pages
  • 93
  • 94
  • 95
  • Next
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
Filings
1,130